SmithKline Beecham and Swedish Bacteriological Laboratories (SBL Vaccin AB) have signed an agreement to develop and commercialize vaccines to protect against diarrhoea caused by enterotoxigenic Escherichia coli and cholera.
Under the terms of the agreement, SBL will develop and manufacture the vaccines. SmithKline Beecham will register and market the vaccines on a worldwide basis except in the Nordic countries and the Baltics, where SBL will retain marketing rights.
Clinical studies to date with the oral cholera vaccine, reports SKB, have shown that it provides superior protection to currently available injectable vaccines and demonstrates high immunogenicity with a very low adverse event profile.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze